Preclinical Alzheimer's disease: Definition, natural history, and diagnostic criteria
Why is this work in the frame?
A frame that forgets how it found something cannot be audited. These are the routes that admitted this work.
Machine scores (provisional)
Baseline scores from an immature model (maturity gate not passed, 7 training rounds). Scores rank; they never assert a category.
The two teacher heads of the student model, read on this work. A score orders the frame for review; it never asserts a category, and the validation status ships verbatim with every row.
- Teacher spread
- 0.291 · how far apart the two teachers sit on this one work
- Validation status
score_only:v0-immature-baseline· verbatim from the scoring run: score_only means the number may rank works, and no category label ships from it
Abstract
During the past decade, a conceptual shift occurred in the field of Alzheimer's disease (AD) considering the disease as a continuum. Thanks to evolving biomarker research and substantial discoveries, it is now possible to identify the disease even at the preclinical stage before the occurrence of the first clinical symptoms. This preclinical stage of AD has become a major research focus as the field postulates that early intervention may offer the best chance of therapeutic success. To date, very little evidence is established on this "silent" stage of the disease. A clarification is needed about the definitions and lexicon, the limits, the natural history, the markers of progression, and the ethical consequence of detecting the disease at this asymptomatic stage. This article is aimed at addressing all the different issues by providing for each of them an updated review of the literature and evidence, with practical recommendations.
Fetched live from OpenAlex and de-inverted. Abstracts are not stored in this database: the inverted indexes are 8.6 GB of the frame’s 9.3 GB of text, and the host has 13 GB free.
The record
- Venue
- Alzheimer s & Dementia
- Topic
- Dementia and Cognitive Impairment Research
- Field
- Medicine
- Canadian institutions
- Douglas Mental Health University InstituteUniversity of British Columbia
- Funders
- Janssen PharmaceuticalsEngineering and Physical Sciences Research CouncilMcDonnell Center for Systems NeuroscienceUniversity of California, San DiegoGenentechNational Institutes of HealthNational Institute of General Medical SciencesH. Lundbeck A/SServierAvid RadiopharmaceuticalsUniversité Pierre et Marie CurieFujirebio EuropeVetenskapsrådetEisaiAgence Nationale de la RechercheEU Joint Programme – Neurodegenerative Disease ResearchNational Institute on AgingNational Institute for Health and Care ResearchCenter for Innovative MedicineNorthern California Institute for Research and EducationAssociation France ParkinsonDanoneFondation Brain CanadaLes Laboratories Pierre FabreAXA Research FundFondation pour l'Aide à la Recherche sur la Sclérose en PlaquesPfizerBiogenAstraZenecaEli Lilly and CompanyTau ConsortiumBristol-Myers SquibbSanofiEconomic and Social Research CouncilTauRx PharmaceuticalsCanadian Institutes of Health ResearchIpsenBundesinstitut für Arzneimittel und MedizinprodukteAlzheimer's AssociationFondation pour la Recherche sur AlzheimerMinistero della SaluteAmgenCalifornia Institute for Regenerative Medicine
- Keywords
- Natural historyDiseaseNatural (archaeology)MedicineHistoryPathologyInternal medicine
- Has abstract in OpenAlex
- yes